Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 725-736

  Kuna, P ^a   Peters, M J ^b   Manjra, A I ^c   Jorup, C ^d   Naya, I P ^d   Martinez Jimenez N E ^e   Buhl, R ^f  

^a N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c Westville Hospital   (South Africa)

^d ASTRAZENECA R AND D   (Sweden)

^e CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; STEROID; TERBUTALINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; GASTRITIS; HOSPITALIZATION; HUMAN; LOG RANK TEST; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; RECURRENCE; TREATMENT OUTCOME;

EID: 34247095987     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01338.x     Document Type: Article

References (37)

1. Aalbers R, Backer V, Kava TT et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225-40.
2. Lalloo UG, Malolepszy J, Kozma D et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123: 1480-7.
3. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527-34.
4. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-7.
5. Partridge MR, Van der MT, Myrseth SE et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13.
6. Angus R, Reagon R, Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract 2005; 59: 156-62.
7. Gibson PG, Powell H, Coughlan J et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; 1: CD001117.
8. Wilson DH, Adams RJ, Appleton SL et al. Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust 2003; 178: 483-5.
9. O'Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-36.
10. Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246-56.
11. Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-53.
12. Vogelmeier C, D'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-28.
13. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2006. http://www.ginasthma.com (accessed January 2007).
14. Dahl R, Chuchalin A, Gor D et al. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006; 100: 1152-62.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-44.
16. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 lg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95: 136-46.
17. van Noord JA, Lill H, Diaz TC et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 mcg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus (TM) in patients with moderate to severe asthma. Clin Drug Investig 2001; 21: 243-55.
18. Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
19. Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: W.B. Saunders Company, 1971.
20. Juniper EF, O'Byrne PM, Guyatt GH et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-7.
21. Juniper EF, Svensson K, Mork AC et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-8.
22. Juniper EF, Buist AS, Cox FM et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265-70.
23. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1: 121-9.
24. Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-7.
25. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-11.
26. Barnes PJ. A single inhaler for asthma? Am J Respir Crit Care Med 2005; 171: 95-6.
27. Gibson PG. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J 2005; 25: 397-9.
28. Tattersfield AE, Postma DS, Barnes PJ et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160: 594-9.
29. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000; 117: 440-6.
30. Miller-Larsson A, Mattsson H, Hjertberg E et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623-30.
31. Jendbro M, Johansson CJ, Strandberg P et al. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001; 29: 769-76.
32. Harrison TW, Oborne J, Newton S et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-5.
33. FitzGerald JM, Becker A, Sears MR et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-6.
34. Palmqvist M, Ibsen T, Mellen A et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244-9.
35. van Veen A, Weller FR, Wierenga EA et al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 2003; 16: 153-61.
36. Tintinger GR, Anderson R, Theron AJ et al. Comparison of the effects of selective and non-selective beta-adrenoceptor agonists on the pro-inflammatory activities of human neutrophils in vivo. Inflammation 2000; 24: 239-49.
37. Price D, Wiren A, Kuna P. Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone (S/F). Eur Respir J 2006; 28 (Suppl. 50): P1274.